The Neo-Bioscore staging system, which evolved from the CPS + EG staging system, encompasses pretreatment clinical stage, posttreatment pathological stage, and tumor biological markers (estrogen receptor [ER], human epidermal growth factor receptor 2 [HER2], and grade), and has been recognized as being an excellent algorithm for assessing the prognosis of patients treated with NAC [4]. This evidence concerns the gene ESR1 and neoplasm.